This biotech company develops an oral prescription drug candidate for the treatment and prevention of Alzheimer's disease. Their therapeutic approach targets specific pathways implicated in neurodegeneration to slow disease progression.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for neurodegenerative diseases like Alzheimer's and Parkinson's often focus on managing symptoms rather than addressing the underlying causes of disease progression. A key factor in these diseases is the impairment of cerebral metabolism, which reduces the brain's energy supply and contributes to neuronal dysfunction.
Solution
Mitargos is developing a novel oral therapeutic designed to restore aging cerebral metabolism and reverse neurodegeneration. Their approach targets the root cause of diseases like Alzheimer's and Parkinson's by revitalizing the brain's energy supplies. By improving energy production and reactivating existing neuronal networks, the therapy aims to enhance the brain's ability to control and modify neurodegenerative processes, regardless of their origins or genetic factors. This approach seeks to go beyond symptom management by enabling the recovery of energy production in the brain.
Target Audience
The primary target audience includes individuals at risk of or affected by neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as healthcare providers specializing in neurology and geriatric care.
Features
- Oral prescription drug candidate for the treatment and prevention of Alzheimer's and Parkinson's disease
- Targets the deficit in cerebral metabolism, a root cause of neurodegenerative diseases
- Aims to revitalize the brain's energy supplies
- Designed to reactivate existing neuronal networks
- Seeks to enhance the brain's ability to control and modify neurodegenerative processes